Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative-Reference-Cited by-同舟云学术

Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: the MedeA initiative

Published:2020-09-01 Issue:3 Volume:35 Page:
ISSN:2191-0162
Container-title:Drug Metabolism and Drug Interactions
language:en
Short-container-title:

Author:

LLerena Adrián¹²³,Peñas-LLedó Eva¹²,de Andrés Fernando¹³^ORCID,Mata-Martín Carmen¹³,Sánchez Cristina L.¹³,Pijierro Agustín¹⁴,Cobaleda Jesús¹²⁵

Affiliation:

1. INUBE Extremadura Biosanitary Research Institute, Badajoz , Spain

2. Faculty of Medicine , University of Extremadura, Badajoz , Spain

3. CICAB Clinical Research Center, Pharmacogenetics and Personalized Medicine Unit , Badajoz University Hospital, Extremadura Health Service, B adajoz , Spain

4. Department of Internal Medicine , Badajoz University Hospital, Extremadura Health Service, Badajoz , Spain

5. Ciudad Jardín Primary Health Care Center , Extremadura Health Service, Badajoz , Spain

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology (medical)

Link

https://www.degruyter.com/document/doi/10.1515/dmpt-2020-0143/pdf

Reference8 articles.

1. Reisberg, S, Krebs, K, Lepamets, M, Kals, M, Mägi, R, Metsalu, K, et al. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genet Med 2019 Jun;21:1345–54. https://doi.org/10.1038/s41436-018-0337-5.

2. LLerena, A, Peñas-Lledó, EM. Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice. Drug Metab Pers Ther 2015;30:143–5. https://doi.org/10.1515/dmdi-2020-0143.

3. LLerena, A, Berecz, R, de la Rubia, A, Fernández-Salguero, P, Dorado, P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 2001 Dec;23:616–20. https://doi.org/10.1097/00007691-200112000-00004.

4. Llerena, A, Berecz, R, de la Rubia, A, Norberto, MJ, Benítez, J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000;22:397–401. https://doi.org/10.1097/00007691-200008000-00006.

5. Berecz, R, LLerena, A, de la Rubia, A, Gómez, J, Kellermann, M, Dorado, P, et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 2002 Nov;35:231–4. https://doi.org/10.1055/s-2002-36389.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision medicine for Defence?;BMJ Military Health;2024-08-24

2. Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations;Journal of Personalized Medicine;2022-12-05